Fate Therapeutics (FATE) Stock: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$2.17
0.10 (4.83%)
â˛
5d:
+4.83%
30d:
-8.82%
90d:
-13.55%
WAIT
LOW Confidence
Analysis Updated: Oct 28, 2026 12:00 AM ET
Earnings: Nov 12, 2026
13d
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $2.17, which is considered fair relative to its 30-day fair value range of $1.99 to $2.39.
Technical Outlook: Technically, FATE is in a downtrend. The price is approaching resistance at $2.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.74 (+164.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FATE is in a downtrend. The price is approaching resistance at $2.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.74 (+164.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.99 -
$2.39
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 164.7% below Wall St target ($5.74)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.99 -
$2.39
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.18
Current Trend
Downtrend
Technical data as of
Oct 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.24
Wall Street Target
$5.74
(+164.7%)
Revenue Growth (YoY)
9.2%
Share & Embed Analysis
Last updated: October 28, 2026 10:57 PM ET
Data refreshes hourly during market hours. Next update: 11:57 PM
Data refreshes hourly during market hours. Next update: 11:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$259 | 67 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 70 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 49 HOLD |
|
SNDX
Syndax Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$37 | 75 BUY |
